Cite
HARVARD Citation
Goldenberg, R. et al. (2017). Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, obesity & metabolism. 19 (3), pp. 394-400. [Online].